Synapsoft logo
AI Insights from Disclosures
Searching...
Penetrium Bioscience Inc. 187660
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
Penetrium Bioscience Inc. is a contract research organization (CRO) that provides services across the entire range of clinical trial activities to pharmaceutical companies, biotech ventures, and others. Bringing a new drug to market requires conducting phased clinical trials (Phase 1, 2, and 3) over a period ranging from as little as five years to an average of ten years, and the company undertakes all or part of this clinical trial work on behalf of client companies.
Representative Director 조원동, 진근우(공동 대표이사)
Founded October 31, 2003
Corporation Type KOSDAQ
Industry Classification Research and experimental development on medical sciences and pharmacy
Corporate number 11011-2887193
Business number 101-81-98897
Phone Number 02-730-1457
Fax Number 02-722-0155
Website hdadmbio.com
Company Address 19 Saemunan-ro 5-gil, Jongno-gu, Seoul
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant